The market expects McKesson (MCK) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on February 7, 2024, might help the stock move higher if these key numbers are ...

Zacks排名系统 - Zacks专注于基于盈利预期和预期修订的排名系统，寻找优质股票[1] 价值投资策略 - 价值投资是发现强势股票的首选方法之一[2] McKesson股票分析 - McKesson (MCK)是一只值得关注的股票，目前具有2（买入）的Zacks排名和价值方面的A级评分[4] - MCK的PEG比率为1.53，略低于行业平均值1.73[5] - MCK的P/CF比率为15.63，相对于行业平均值20.18，显示出被低估的迹象[6] - 这些数据显示出MCK目前可能被低估，结合其盈利前景的强劲，MCK现在是一只令人印象深刻的价值股票[7]

McKesson Corporation (MCK) recently announced its plan to sell Rexall Pharmacy Group, the Canadian drugstore chain that the company bought for about $2.2 billion seven years ago.McKesson bought the business in 2016 from Katz Group to solidify its position in Canada's pharmaceutical supply chain.Price PerformanceFor the past six months, MCK’s shares have rallied 19.9% against the industry’s decline of 2.4%. The S&P 500 increased 3.9% in the same time frame.Image Source: Zacks Investment ResearchMore on the N ...

McKessonCorporation (MCK) is well-poised for growth, backed by strategic collaborations and strength in the Distribution Solutions segment. However, the company’s opioid-related litigation expenses are a potential threat.Shares of this currently Zacks Rank #2 (Buy) company have risen 27.4% in the past year compared with the industry’s 9% growth. The S&P 500 Index has increased 20.6% in the same time frame.McKesson is a healthcare services and information technology company with a market capitalization of $6 ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed alongside ...

Shares of McKesson Corporation (MCK) scaled a new 52-week high of $485.22 on Jan 3, 2024, before closing the session slightly lower at $480.34.Over the past year, this Zacks Rank #3 (Hold) stock has gained 28.4% compared with 11.7% growth of the industry and a 24.4% rise of the S&P 500 Composite.Over the past five years, the company registered earnings growth of 15.4% compared with the industry’s 9.1% rise. The company’s long-term expected growth rate of 10.5% compares with the industry’s growth projection ...

IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its third quarter fiscal 2024 financial results after market close on Wednesday, February 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. McKesson management will be participating in the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024. The live webcast for each event will be available on McKesson’s Inves ...

公司活动 - 麦科森公司将于2024年2月7日下午4:30在东部时间举行投资者收益电话会议，审查其财务业绩[1] - 麦科森公司将参加2024年1月9日举行的第42届摩根大通医疗保健大会[1] 公司业务 - 麦科森公司是一家多元化的医疗保健服务领导者，致力于提高全球患者的健康结果[2]

财务数据和关键指标变化 - 公司第二季度收入增长10%至772亿美元 [7] - 调整后每股收益为6.23美元,同比增长14% [37] - 公司预计全年调整后每股收益将增长14%至17% [65] 各条业务线数据和关键指标变化 - 美国制药分部收入增长16%,主要受益于处方量增加和特药销售增长 [41] - 处方技术解决方案分部收入增长12%,主要受益于获取解决方案业务量增加 [44] - 医疗-外科解决方案分部收入持平,受到新冠检测和疫苗相关业务下降的影响 [46] 各个市场数据和关键指标变化 - 初级护理市场流量放缓,导致医疗-外科解决方案分部业绩下滑 [46][49] 公司战略和发展方向及行业竞争 - 公司持续投资于肿瘤和生物医药服务平台,扩大差异化优势 [18][21] - 公司在处方技术解决方案分部持续投资,以提升产品组合和用户体验 [23][24][25] - 公司在分销网络、数据分析等方面持续投资,以支持业务增长 [59][60] 管理层对经营环境和未来前景的评论 - 管理层对公司业务保持信心,预计未来将继续保持良好增长势头 [6][27] - 管理层认为初级护理市场流量放缓可能持续至2024财年剩余时间 [59] 问答环节重要的提问和回答 问题1 **Eric Percher 提问** 询问处方技术解决方案分部收入和利润增长的驱动因素 [69][70] **Britt Vitalone 回答** 解释了处方量增长、新药品上市以及年度客户验证项目等因素对该分部业绩的影响 [70][71] 问题2 **Lisa Gill 提问** 询问处方技术解决方案分部第二半年业绩预期下滑的原因 [74][75] **Britt Vitalone 回答** 解释了该分部存在季节性因素,如年度客户验证项目,以及GLP-1药品销量增长放缓等因素 [75][76][77] 问题3 **Charles Rhyee 提问** 询问Rite Aid破产相关的应收账款坏账准备计提情况 [81][82][83] **Britt Vitalone 回答** 解释了公司已经计提了部分坏账准备,并与Rite Aid达成了临时分销协议,缩短了信用期限 [82][83]

McKesson Corporation Second Quarter Fiscal 2024 Earnings Call Cautionary Statements Cautionary Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward- looking statements may be identified by their use of terminology such as “believes,” “expects,” “anticipates,” “may,” “will,”“should,” “seeks,” “approximately,” “intends,” “projects,” “plans,” “estimates,” “targets,” or the ...